Managing patients in the perioperative setting receiving novel oral anticoagulation agents
for thromboprophylaxis or stroke prevention with atrial fibrillation is an important …

Patients undergoing surgery receive anticoagulation for perioperative thromboprophylaxis
or ischemic cardiovascular disease. Because anticoagulants may also potentiate bleeding …

New oral anticoagulants, including dabigatran, rivaroxaban, and apixaban, have been
recently approved for primary and secondary prophylaxis of thromboembolic conditions …

NOACs like dabigatran etexilate, rivaroxaban, apixaban and edoxaban are effective
alternatives to warfarin in primary and secondary prophylaxis of thromboembolic conditions …

New oral anticoagulants like the direct thrombin inhibitor, dabigatran (P radaxa®), and factor
X a‐inhibitors, rivaroxaban (X arelto®) and apixaban (E liquis®) are available for …

The past decade has witnessed an explosion in the clinical development of new orally-
administered anticoagulant drugs aimed at complementing vitamin K antagonists and …

The new oral anticoagulants dabigatran, rivaroxaban and apixaban have advantages over
warfarin which include no need for laboratory monitoring, less drug–drug interactions and …

Direct new oral anticoagulants (NOACs)–inhibitors of thrombin or factor Xa–are intended to
be used largely in the treatment of venous thromboembolic disease or the prevention of …

Since 2011, data on patients exposed to direct oral anticoagulants (DOAs) while undergoing
invasive procedures have accumulated. At the same time, an increased hemorrhagic risk …

Background The use of prothrombin complex concentrates and the role of plasma
concentration of anticoagulants in the management of bleeding in patients treated with direct …